Novocure (NVCR) recognized first non-small cell lung cancer revenues ahead of schedule, with 92 Optune Lua prescriptions for NSCLC received in the quarter and 62 active patients on the treatment, H.C. Wainwright tells investors in a research note. The firm says the positive ramp-up continues and CE Mark has been secured, and estimates $10M in revenue for NSCLC in 2025, up from its prior estimate of $6M. H.C. Wainwright has a Buy rating and $38 price target on the stock.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue